

Reference number(s)
2864-H

SPECIALTY QUANTITY LIMIT PROGRAM

INBRIJA (levodopa inhalation powder)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of “off” episodes in patients with Parkinson’s disease fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Inbrija 42 mg (for oral inhalation) 60-capsule carton	5 cartons per 30 days	Inhale the contents of two capsules as needed for off symptoms, up to 5 times daily.
Inbrija 42 mg (for oral inhalation) 92-capsule carton	4 cartons per 30 days	

III. REFERENCES

1. Inbrija [package insert]. Ardsley, NY: Acorda Therapeutics, Inc.; December 2018.